Pharma BD Deal Intelligence
A $1.173B option-and-collaboration deal that gave Takeda access to Denali's blood-brain-barrier delivery platform for neurodegenerative disease programs, backed by $40M upfront plus a $110M equity stake. The lead ATV:TREM2 candidate later hit an FDA clinical hold and was discontinued.
Up-to-$1.2B neurodegenerative disease collaboration launched by Takeda, Denali. Denali receives $40 million upfront and $110 million equity investment.
Takeda and Denali Therapeutics collaborate to develop and commercialize therapies for neurodegenerative diseases using Denali's Antibody Transport Vehicle…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Takeda entered an option and collaboration agreement with Denali Therapeutics to develop and commercialize biologic products using Denali's Antibody Transport Vehicle (ATV) blood-brain barrier delivery technology for neurodegenerative diseases. The deal covered three programs: ATV:TREM2, ATV:BACE1/Tau, and a third undisclosed discovery-stage program. Takeda paid $40 million upfront, $5 million preclinical milestone, and $110 million in equity investment (~4.21M shares at ~$26.10/share). Total potential deal value up to $1.173 billion. The ATV:TREM2 program (DNL919) later received an FDA clinical hold and was subsequently discontinued.
700K US cases/yr · $30.0B Global neurodegenerative disease therapeutics
Neurodegenerative diseases encompass Alzheimer's, Parkinson's, ALS, MS, and other conditions. Anti-amyloid therapies marked a breakthrough for AD. TREM2 and other neuroinflammation targets are in active development for multiple conditions.
TREM2 agonists, anti-tau antibodies, antisense oligonucleotides, gene therapies. Blood-brain barrier delivery platforms (like Denali's ATV) enabling new modalities. Key players: Biogen, Roche, Lilly, Novartis, Denali.
500K US cases/yr · $15.0B Global Alzheimer's therapeutics (projected with anti-amyloid era)
Alzheimer's disease is the most common cause of dementia. Anti-amyloid antibodies (lecanemab, donanemab) have demonstrated disease modification, though clinical benefit remains modest. Tau-targeting therapies are the next frontier.
Symptomatic: cholinesterase inhibitors, memantine. Disease-modifying: lecanemab (Leqembi), donanemab. Tau-targeting approaches in clinical trials. Key players: Eisai/Biogen (Leqembi), Lilly (donanemab/Kisunla), Roche (gantenerumab failed).
Takeda partnered with Denali for ATV blood-brain barrier delivery technology for neurodegeneration.
Phase 1 revealed narrow therapeutic window. Moderate reversible hematologic effects at highest dose.
DNL919 discontinued. Back-up molecules in preclinical. ATV technology platform still of interest.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. (this deal) | 2018 | $1.2B | 64 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Insilico Medicine Inc. | 2026 | $600M | 54 |
← Browse all deals · How we score deals
More: 2018 deals · Takeda Pharmaceutical Company Ltd. deals · Neurology deals